Oruka Therapeutics
ORKA
66 hedge funds and large institutions have $607M invested in Oruka Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 5 closing their positions.
480% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 5
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
57% more funds holding
Funds holding: 42 → 66 (+24)
18.51% more ownership
Funds ownership: 70.17% → 88.68% (+19%)
0% more capital invested
Capital invested by funds: $604M → $607M (+$2.45M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.2M |
| 4 |
BlackRock
New York
|
+$17.8M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$11.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$10.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$9.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.97M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$6.31M |
ORKA Hedge Fund Activity: Q4 2024 in Review
66 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2024, worth a combined $607M — up 0.41% from $604M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ORKA positions and 5 closed out — a net gain of 24 holders — while 20 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $38.4M. The largest seller was Deep Track Capital, cutting an estimated $11.8M.
- 66 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2024, up from 42 in Q3 2024.
- Funds reported $607M of Oruka Therapeutics stock for Q4 2024, up 0.41% quarter-over-quarter.
- 29 funds opened new Oruka Therapeutics positions in Q4 2024 and 5 closed out, a net change of +24 holders.
- The largest Oruka Therapeutics buyer in Q4 2024 was Vanguard Group, an estimated $38.4M added.
- The largest Oruka Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2024.